D Lovick
University of Minnesota
3 Papers
D Lovick is an academic researcher from University of Minnesota. The author has contributed to research in topics: Internal medicine & Clinical endpoint. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
Linda M. Liau,Keyoumars Ashkan,Steven Brem,Jian Campian,John E. Trusheim,Fabio M. Iwamoto,David Tran,George Ansstas,Charles Cobbs,Jason Heth,Michael Salacz,Stacy D. D’Andre,Robert Aiken,Yaron A. Moshel,Joo Yeon Nam,Clement Pillainayagam,Stephanie Ann Wagner,Kevin A. Walter,Rekha Chaudhary,Samuel Goldlust,Ian Lee,Daniela A. Bota,Heinrich Elinzano,Jai Grewal,Kevin O. Lillehei,Tom Mikkelsen,Tobias Walbert,Steven R. Abram,Andrew Brenner,Matthew G. Ewend,Simon Khagi,D Lovick,Jana Portnow,Lyndon Kim,William G Loudon,Nina L. Martinez,Reid C. Thompson,David Avigan,Karen Fink,Francois J. Geoffroy,Pierre Giglio,Oleg Gligich,Dietmar Krex,Scott Lindhorst,Jose Lutzky,Hans Joerg Meisel,Minou Nadji-Ohl,L. Sanchin,Andrew E. Sloan,Lynne P. Taylor,Julian K. Wu,Erin M. Dunbar,Arnold B. Etame,Santosh Kesari,David Mathieu,David Piccioni,David S. Baskin,Michel Lacroix,Sven-Axel May,Pamela New,Timothy J. Pluard,Steven A. Toms,Victor Tse,Scott Peak,John L. Villano,James Battiste,Paul Mulholland,Michael Pearlman,Kevin Petrecca,Michael Schulder,Robert M. Prins,Alton L. Boynton,Marnix L. Bosch +72 more
TL;DR: In this article , treatment with autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) was associated with improved overall survival (OS) for patients with newly diagnosed glioblastoma (nGBM) and recurrent gliomatosis (rGBM), compared with standard of care (SOC).
Enhancement of nigral graft survival in rat brain with the systemic administration of synthetic fibronectin peptide V.
Wei Ming Duan,L.-R Zhao,Marcus A. Westerman,D Lovick,Leo T. Furcht,James B. McCarthy,Walter C. Low +6 more
TL;DR: The results demonstrate that the systemic administration of synthetic fibronectin peptide V can dramatically increase the survival of nigral grafts in the brain and substantially reduce the number of apoptotic cells in the graft site, suggesting that this peptide may exert a beneficial effect on survival of neural grafts through an anti-apoptotic mechanism.
26
Ctim-27. autologous tumor lysate-loaded dendritic cell vaccination improves survival in patients with newly diagnosed and recurrent glioblastoma: survival results from a phase 3 trial
Linda M. Liau,Keyoumars Ashkan,Steven Brem,Jian Campian,John E. Trusheim,Fabio M. Iwamoto,David Tran,George Anstass,Charles K. Cobbs,Jason Heth,Michael Salacz,Stacy D. D’Andre,Robert Aiken,Yaron A. Moshel,Joo Yeon Nam,Clement Pillainayagam,Stephanie Ann Wagner,Kevin A. Walter,Rekha Chaudary,Samuel Goldlust,Ian Lee,Daniela A. Bota,Heinrich Elinzano,Jai Grewal,Kevin O. Lillehei,Tom Mikkelsen,Tobias Walbert,Steven R. Abram,Andrew Brenner,Matthew G. Ewend,Simon Khagi,D Lovick,Jana Portnow,Lyndon Kim,William G Loudon,Nina L. Martinez,Reid C. Thompson,David Avigan,Karen Fink,Francois J. Geoffroy,Pierre Giglio,Oleg Gligich,Dietmar Krex,Scott Lindhorst,Jose Lutzky,Hans Joerg Meisel,Minou Nadji-Ohl,L. Sanchin,Andrew E. Sloan,Marnix L. Bosch +49 more
TL;DR: In this article , the authors evaluated whether adding an autologous tumor lysate-loaded dendritic cell vaccine (murcidencel) to standard of care (SOC) extends survival in glioblastoma patients.
4